Disc Med­i­cine goes pub­lic in re­verse merg­er with strug­gling Gem­i­ni Ther­a­peu­tics

Af­ter li­cens­ing a failed Roche schiz­o­phre­nia drug last year, Disc Med­i­cine is go­ing pub­lic via a re­verse merg­er with Gem­i­ni Ther­a­peu­tics.

The com­bined com­pa­ny, while …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER